InflaRx Reports Second Quarter 2022 Financial & Operating Results

ABIVAX PHASE 3 PROGRAM WITH OBEFAZIMOD IN ULCERATIVE COLITIS PROGRESSES WITH US IRB APPROVAL

QUANTRO Therapeutics collaborates with Boehringer Ingelheim to develop drug candidates interfering with transcriptional regulators

Spexis provides business update

Destiny Pharma: Chair’s Investor Update

Destiny Pharma: Publication of new data on NTCD-M3 confirms potential as an effective treatment for prevention of C. difficile infections

Marinomed to pause issuing of tranches of Convertible Notes Funding Program to Nice & Green

iOmx Therapeutics Announces the Appointment of Three New Supervisory Board Members

Spexis announces business update call to be held on July 28th

CEVEC’s license partner RZNOMICS Inc. receives approval to initiate clinical development of CAP® Ad Technology-produced gene therapy vector in liver cancer patients